Global Alzheimer Prevalence and Drugs Demand
EXECUTIVE SUMMARY
The report on “Global Alzheimer Prevalence and Drugs Demand” includes the overall market for the treatment of Alzheimer, performance of drugs by sales and market share. In terms of countries we have mentioned United States and China. US section talks about prevalence of the disease, overall market size by value further segmented into drugs market with present and historical performance also forecasting helps to analyse the future of the industry. In China section we have discussed a general overview of the disease, prevalence, causes and medicine market share. Industry trends section represents various factors accounting for any change in the treatment and new developments. Report also includes factors responsible for the treatment demand and development of new therapies in the driving forces section. The report also discusses competition prevailing in the present industry and overview of leading players business and business strategies.
Market is showing a constant growth rate largely driven by aging population but still there is no cure for the disease. The number of Americans with Alzheimer’s disease and other dementias will grow each year as the proportion of the U.S. population that is over age 65 continues to increase.
Scope of the Report
The report on “Global Alzheimer Prevalence and Drugs Demand” includes the overall market for the treatment of Alzheimer, performance of drugs by sales and market share. In terms of countries we have mentioned United States and China. US section talks about prevalence of the disease, overall market size by value further segmented into drugs market with present and historical performance also forecasting helps to analyse the future of the industry. In China section we have discussed a general overview of the disease, prevalence, causes and medicine market share. Industry trends section represents various factors accounting for any change in the treatment and new developments. Report also includes factors responsible for the treatment demand and development of new therapies in the driving forces section. The report also discusses competition prevailing in the present industry and overview of leading players business and business strategies.
Market is showing a constant growth rate largely driven by aging population but still there is no cure for the disease. The number of Americans with Alzheimer’s disease and other dementias will grow each year as the proportion of the U.S. population that is over age 65 continues to increase.
- Three major primary medications on the market for Alzheimer disease - Aricept, Exelon, and Razadyne are AChE inhibitors, and the fourth medication, Namenda, is a NMDAr antagonist.
- The global Alzheimer's disease treatment market was valued at USD8.3 billion in 2010. By geography, North America is heading the market with 37.73% share of the global Alzheimer market in 2010.
- The leading markets for Alzheimer disease therapeutics were United States, Europe, and Japan accounting for a large share of the overall market.
- The top 5 pharmaceutical companies in this market are Eisai, Forest Pharmaceutical, Novartis, Pfizer, and Johnson & Johnson.
- In 2009, Namenda market share has reached to 20.94% from 20.63% in 2008. Namenda is covered by a U.S. method of use patent which was expected to expire in 2010 but now extended to 2015.
- Aricept accounted for the royal share of the market (32.34%), Exelon and razadyne accounted for 7.85% and 5.62% market share in 2009.
- In US, Aricept is the market leader with 62.61% share in 2010 as compared to 53.90% in 2009. Demand has been slowed in recent past years also contribution of other players and expiry of some of the patents affected the sales in US.
- The mental disorder treatment is driving Chinese psychiatric drug market which represented USD250 million in 2007 and now it is expected to reach to USD1.2 billion in 2013.
- Huperzine A (Chinese brands) and donepezil (Eisai's Aricept, Chinese brands) are two leading drugs dominating the treatment of Alzheimer's disease and the overall Alzheimer's disease market in China constituted around USD17.74 million in 2009.
- The AD market could cross USD9.0 billion by 2016 with the introduction of disease-modifying drugs (DMDs). AD is likely to be the primary driver of growth in the larger central nervous system market from 2005 to 2011, expected to grow with a compound annual growth rate (CAGR) of 1.21%
Scope of the Report
- The report gives a detailed analysis of the Global Alzheimer prevalence and drugs demand with discussion of industries past performance, present analyses and future outlook of the industry.
- We have discussed US Alzheimer prevalence and overall market in detail, further segmented by drugs, market share and market value.
- US Alzheimer drugs section will help the various medical companies worldwide to measure the potential of the market in the region and introduce drugs which may slow down the effect of the disease.
- Industry trends provide opportunities prevailing and potential market wherein a persisting demand exists for curing the disease.
- We have discusses industry players positioning, profiled major players and further scope for new and existing players.
- Present report may help present and new players seeking to enter into new geographies and looking for new prospects and formulate strategies.
- Forecasting plays an important part in the report which directs market players to build up strategies and shows industry scope.
1. INTRODUCTION
1.1. Dementia and Alzheimer Prevalence
2. GLOBAL ALZHEIMER MARKET AND PERFORMANCE
2.1. Market Size
2.2. Alzheimer Drugs Demand
3. ALZHEIMER’S MARKET: UNITED STATES
3.1. Prevalence of the Disease
3.2. Market Size
3.2.1. US Alzheimer Drugs Market
4. CHINA
5. INDUSTRY TRENDS
5.1. Ranbaxy gets Approval for Alzheimer’s drug
5.2. Wockhardt received US FDA approval for Alzheimer’s drug Memantine
5.3. Opportunities Persist in the Global Market
5.4. Canada A New Destination for Alzheimer Treatment
5.5. RFID Chip Implants Planned for Alzheimer's Patients
5.6. Herbal supplement improves memory in patients at risk of Alzheimer's
5.7. Scientists Develop Blood Test to Detect Alzheimer's disease
5.8. Government Regulation
5.9. Future Outlook
6. DRIVING FORCES
6.1. Prevalence Rate Increases with Aging Population
6.2. Urbanization is More Prone to the Risk of Dementia
6.3. Western Regions Shows higher Risk than Eastern Parts
7. COMPETITIVE LANDSCAPE
7.1. Drugs Competition
7.2. Market Players Profile
7.2.1. Forest Laboratories
7.2.2. Novartis
7.2.3. Elan Corporation
1.1. Dementia and Alzheimer Prevalence
2. GLOBAL ALZHEIMER MARKET AND PERFORMANCE
2.1. Market Size
2.2. Alzheimer Drugs Demand
3. ALZHEIMER’S MARKET: UNITED STATES
3.1. Prevalence of the Disease
3.2. Market Size
3.2.1. US Alzheimer Drugs Market
4. CHINA
5. INDUSTRY TRENDS
5.1. Ranbaxy gets Approval for Alzheimer’s drug
5.2. Wockhardt received US FDA approval for Alzheimer’s drug Memantine
5.3. Opportunities Persist in the Global Market
5.4. Canada A New Destination for Alzheimer Treatment
5.5. RFID Chip Implants Planned for Alzheimer's Patients
5.6. Herbal supplement improves memory in patients at risk of Alzheimer's
5.7. Scientists Develop Blood Test to Detect Alzheimer's disease
5.8. Government Regulation
5.9. Future Outlook
6. DRIVING FORCES
6.1. Prevalence Rate Increases with Aging Population
6.2. Urbanization is More Prone to the Risk of Dementia
6.3. Western Regions Shows higher Risk than Eastern Parts
7. COMPETITIVE LANDSCAPE
7.1. Drugs Competition
7.2. Market Players Profile
7.2.1. Forest Laboratories
7.2.2. Novartis
7.2.3. Elan Corporation
LIST OF FIGURES
Figure 1: Cost of Dementia and Comparison With Company’s Revenues
Figure 2: Global Alzheimer Market by Value (2006-2010)
Figure 3: Global Alzheimer Drugs Market Share in 2009
Figure 4: Lifetime Risks for Alzheimer’s by Age and Sex
Figure 5: US Alzheimer Therapeutic Market (2007-2011E)
Figure 6: Medicine Market Share in China in 2010
Figure 7: Projected Number of people Aged 65 and Over in US Population with Alzheimer Disease
Figure 8: Global Alzheimer therapeutic Market Forecast by Value (2010-2015E)
Figure 9: Alzheimer Prevalence Rate in Aging Population
Figure 1: Cost of Dementia and Comparison With Company’s Revenues
Figure 2: Global Alzheimer Market by Value (2006-2010)
Figure 3: Global Alzheimer Drugs Market Share in 2009
Figure 4: Lifetime Risks for Alzheimer’s by Age and Sex
Figure 5: US Alzheimer Therapeutic Market (2007-2011E)
Figure 6: Medicine Market Share in China in 2010
Figure 7: Projected Number of people Aged 65 and Over in US Population with Alzheimer Disease
Figure 8: Global Alzheimer therapeutic Market Forecast by Value (2010-2015E)
Figure 9: Alzheimer Prevalence Rate in Aging Population
LIST OF TABLES
Table 1: Global Alzheimer Drugs Sales in 2009
Table 2: Alzheimer Therapeutic Drugs Market in US (2001-2010)
Table 3: Expected Bapineuzumab Sales (2010-2015E)
Table 4: Alzheimer Drugs Comparison
Table 5: Clinical Trials
Table 6: Forest Laboratories Revenues by Business Segments
Table 7: Novartis Revenue and Operating Income (2006-2010)
Table 8: Elan Revenues by Business Segments
Table 1: Global Alzheimer Drugs Sales in 2009
Table 2: Alzheimer Therapeutic Drugs Market in US (2001-2010)
Table 3: Expected Bapineuzumab Sales (2010-2015E)
Table 4: Alzheimer Drugs Comparison
Table 5: Clinical Trials
Table 6: Forest Laboratories Revenues by Business Segments
Table 7: Novartis Revenue and Operating Income (2006-2010)
Table 8: Elan Revenues by Business Segments
